Two-Drug attack on tough leukemia in young patients
NCT ID NCT05464836
Summary
This study tested whether combining two drugs, CB-103 and venetoclax, could help control a hard-to-treat type of blood cancer called T-cell acute lymphoblastic leukemia (T-ALL) in adolescents and young adults. The trial was for patients aged 12 to 60 whose cancer had returned or did not respond to prior treatments. The main goals were to check the safety of the combination and see if it could reduce or eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.